|
gptkbp:instanceOf
|
gptkb:drug
antihistamine
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:ATCCode
|
gptkb:R06AX26
|
|
gptkbp:bioavailability
|
30% to 41%
|
|
gptkbp:brand
|
gptkb:Allegra
Telfast
Fexodane
|
|
gptkbp:CASNumber
|
153439-40-8
|
|
gptkbp:category
|
second-generation antihistamine
|
|
gptkbp:chemicalFormula
|
C32H39NO4
|
|
gptkbp:contraindication
|
hypersensitivity to fexofenadine
|
|
gptkbp:developedBy
|
terfenadine
|
|
gptkbp:discoveredBy
|
gptkb:Marion_Merrell_Dow
|
|
gptkbp:eliminationHalfLife
|
14 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
gptkb:tablet
oral suspension
dispersible tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Fexofenadine
|
|
gptkbp:interactsWith
|
gptkb:erythromycin
gptkb:ketoconazole
antacids containing aluminum or magnesium
|
|
gptkbp:isomerOf
|
(S)-fexofenadine
|
|
gptkbp:legalStatus
|
prescription-only (in some countries)
over-the-counter (in many countries)
|
|
gptkbp:marketedAs
|
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
selective peripheral H1 receptor antagonist
|
|
gptkbp:meltingPoint
|
195–197 °C
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:notableFor
|
non-sedating antihistamine
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
adults
children
elderly
|
|
gptkbp:proteinBinding
|
60% to 70%
|
|
gptkbp:PubChem_CID
|
3348
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
fatigue
headache
drowsiness (rare)
|
|
gptkbp:UNII
|
K4RWD5W2EU
|
|
gptkbp:usedFor
|
allergic rhinitis
chronic urticaria
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Antihistamines_for_systemic_use
gptkb:Allegra
|
|
gptkbp:bfsLayer
|
7
|